Date: 2013-05-08
Type of information: Development agreement
Compound: biosimilar versions of Humira®, Rituxan®, Avastin®, and Herceptin®
Company: Oncobiologics (USA - NJ) Zhejiang Huahai Pharmaceuticals (China)
Therapeutic area: Cancer - Oncology - Autoimmune diseases
Type agreement: development manufacturing production commercialisation
Action mechanism: biosimilar/monoclonal antibody
Disease:
Details: * On May 8, 2013, Oncobiologics announced that Zhejiang Huahai Pharmaceutical Co., Ltd and Oncobiologics have signed an alliance agreement for the development, manufacture and commercialization of biosimilar monoclonal antibody products. The scope of the agreement includes exclusive commercialization by Huahai of four biosimilars developed by Oncobiologics and manufactured in China at a Huahai biologics facility for the China market, and will also establish a co-development and commercialization partnership for launching such biosimilars to more than 30 developed countries, including the U.S., E.U., Japan, Canada and Australia. The partnership will seek local partners to drive commercialization in those 30 countries. The four biosimilars are generic versions of Humira®, Rituxan®, Avastin®, and Herceptin®. These biologics represent annual global revenue of more than $40 billion with more than $20 billion in the countries covered by this agreement. The partnership is planning to launch its first product by late 2016.
Financial terms: Financial terms were not disclosed.
Latest news:
